CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

References

• Abbasi J. Getting pharmacogenomics into the clinic. JAMA. 2016 Oct 18;316(15):1533–1535.
   PubMed Web of Science ®Google Scholar
• Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019 aug 10;394(10197):521–532.
   PubMed Web of Science ®Google Scholar
• pharmgkb.org Accesssed 03 October, 2022. https://www.pharmgkb.org/guidelineAnnotations
   Google Scholar
• PharmVar.org. Pharmacogene Variation Consortium (PharmVar) at. Last accessed on 08 June 2022. https://www.PharmVar.org (Gaedigk et al. 2018, CPT 103:399; Gaedigk et al. 2019, CPT 105:29).
   Google Scholar
• Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci. 2020 01;13(1): 116–124.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb;83(2):234–242.
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021 10;110(4):888–896. .
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015 Feb;79(2):222–240.
   PubMed Web of Science ®Google Scholar
• fda.gov. U.S. Food and Drug Administration. Drug Development and Drug Interactions: table of Substrates, Inhibitors and Inducers. https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm Accessed on 08 june 2022.
   Google Scholar
• rxsaver.com. https://www.rxsaver.com/blog/top-50-prescription-drugs-filled Last accessed on October 11, 2022.
   Google Scholar
• Chanfreau-Coffinier C, Tuteja S, Hull LE, et al. Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs. Pain. 2022 Mar 23.
   Web of Science ®Google Scholar
• Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther. 2004 Dec;76(6):639–647.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011 Mar;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Brown JT, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019 07;106(1):94–102. .
   PubMed Web of Science ®Google Scholar
• Goetz MP, Sangkuhl K, Guchelaar HJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018 05;103(5):770–777. .
   PubMed Web of Science ®Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07;102(1):37–44. .
   PubMed Web of Science ®Google Scholar
• Cicali EJ, Elchynski AL, Cook KJ, et al. How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a Tutorial. Clin Pharmacol Ther. 2021 09;110(3):677–687. .
   PubMed Web of Science ®Google Scholar
• Monte AA, West K, McDaniel KT, et al. CYP2D6 genotype phenotype discordance due to drug-drug interaction. Clin Pharmacol Ther. 2018 11;104(5):933–939.
   PubMed Web of Science ®Google Scholar
• Yang Y, Botton MR, Scott ER, et al. Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing. Pharmacogenomics. 2017 May;18(7):673–685.
   PubMed Web of Science ®Google Scholar
• Jarvis JP, Peter AP, Shaman JA. Consequences of. Front Psychiatry. 2019;10:432.
   PubMedGoogle Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127–134.
   PubMed Web of Science ®Google Scholar
• Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013 Oct;25(5):534–553.
   PubMed Web of Science ®Google Scholar
• Beoris M, Amos Wilson J, Garces JA, et al. CYP2D6 copy number distribution in the US population. Pharmacogenet Genomics. 2016 Feb;26(2):96–99.
   PubMed Web of Science ®Google Scholar
• Fleeman N, Dundar Y, Dickson R, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011 Feb;11(1):1–14.
   PubMed Web of Science ®Google Scholar
• Taylor C, Crosby I, Yip V, et al. A review of the important role of. Genes (Basel). 2020 oct 30;11(11):1295.
   PubMed Web of Science ®Google Scholar
• Gressier F, Ellul P, Dutech C, et al. Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression. Am J Psychiatry. 2014 08;171(8):890.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006 Aug 19;368(9536):704.
   PubMed Web of Science ®Google Scholar
• Suzumura T, Kimura T, Kudoh S, et al. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer. 2012 Dec 04;12:568.
   PubMed Web of Science ®Google Scholar
• Daniel WA, Bromek E, Danek PJ, et al. The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. Biochem Pharmacol. 2022 05;199:115006.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med. 2017 02;19(2): 215–223.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01;19(1):69–76.
   PubMed Web of Science ®Google Scholar
• imshealth.com. IMS Institute for Healthcare Informatics. Medication use and the shifting cost of healthcare - a review of use of medicines in the United States in 2013. https://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI_US_Use_of_Meds_for_2013.pdf. Accessed 08 june 2020
   Google Scholar
• clincalc.com. https://clincalc.com/DrugStats/Top200Drugs.aspx last accessed on October 11, 2022.
   Google Scholar
• PPiO PA. The management of persistent pain in older persons. J Am Geriatr Soc. 2002 Jun;50(6 Suppl):S205–24.
   PubMedGoogle Scholar
• Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007 Dec;7(4):352–356.
   PubMedGoogle Scholar
• Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011 Apr;59(3):385–390.
   PubMed Web of Science ®Google Scholar
• Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988;2:914–915.
   PubMed Web of Science ®Google Scholar
• Lötsch J, Skarke C, Schmidt H, et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther. 2006 Jan;79(1):35–48.
   PubMed Web of Science ®Google Scholar
• Vevelstad M, Pettersen S, Tallaksen C, et al. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol. 2009 Aug;65(8):795–801.
   PubMed Web of Science ®Google Scholar
• Yue QY, Svensson JO, Alm C, et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645.
   PubMed Web of Science ®Google Scholar
• Frost J, Løkken TN, Helland A, et al. Post-mortem levels and tissue distribution of codeine, codeine-6-glucuronide, norcodeine, morphine and morphine glucuronides in a series of codeine-related deaths. Forensic Sci Int. 2016 May;262:128–137.
   PubMed Web of Science ®Google Scholar
• Haffen E, Paintaud G, Berard M, et al. On the assessment of drug metabolism by assays of codeine and its main metabolites. Ther Drug Monit. 2000 Jun;22(3):258–265.
   PubMed Web of Science ®Google Scholar
• Radford H, Simpson KH, Rogerson S, et al. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain. Medicina (Kaunas). 2019 May 28;55(6).
   PubMed Web of Science ®Google Scholar
• He YJ, Brockmöller J, Schmidt H, et al. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol. 2008 Mar;32(2):178–182.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007 Aug;7(4):257–265.
   PubMed Web of Science ®Google Scholar
• Lötsch J, von Hentig N, Freynhagen R, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009 Jun;19(6):429–436.
   PubMed Web of Science ®Google Scholar
• fda.gov. https://www.fda.gov/consumers/consumer-updates/codeine-and-tramadol-can-cause-breathing-problems-children#:~:text=The%20FDA%20is%20warning%20that,tramadol%20for%20use%20in%20children.Last accessed on October 15, 2022.
   Google Scholar
• Paar WD, Poche S, Gerloff J, et al. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53(3–4):235–239.
   PubMed Web of Science ®Google Scholar
• Haage P, Kronstrand R, Josefsson M, et al. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of. Pharmacol Res Perspect. 2018 07;6(4): e00419.
   PubMed Web of Science ®Google Scholar
• Slanar O, Nobilis M, Kvetina J, et al. Miotic action of tramadol is determined by CYP2D6 genotype. Physiol Res. 2007;56(1):129–136.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Naito T, Sato H, et al. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients. Eur J Clin Pharmacol. 2018 Nov;74(11):1461–1469.
   PubMed Web of Science ®Google Scholar
• Bastami S, Haage P, Kronstrand R, et al. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Forensic Sci Int. 2014 May;238:125–132.
   PubMed Web of Science ®Google Scholar
• Lane K, Dixon JJ, McKeown D, et al. Using tramadol to measure CYP2D6 metabolism in critically ill adults. Intensive Care Med. 2014 Aug;40(8):1177–1178.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Keulen JT, Bauer S, et al. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol. 2008 Feb;28(1):78–83.
   PubMed Web of Science ®Google Scholar
• Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1356–1358.
   PubMed Web of Science ®Google Scholar
• Tillman EM, Skaar TC, Eadon MT. Nephrotoxicity in a Patient With Inadequate Pain Control: potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1. Front Pharmacol. 2019;10:1511.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003 Sep;105(1):231–238.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007 Jul;82(1):41–47.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Sun J, Tao Y, et al. A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Pharmacogenomics. 2014 Mar;15(4):487–495.
   PubMed Web of Science ®Google Scholar
• Befort K, Filliol D, Decaillot FM, et al. A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling. J Biol Chem. 2001 Feb 02 276(5):3130–3137.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Stüber F, Muders T, et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg. 2008 Sep;107(3):926–929.
   PubMed Web of Science ®Google Scholar
• Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? Clin Chim Acta. 2014 Feb 15;429:26–29.
   PubMed Web of Science ®Google Scholar
• Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther. 1997 Apr;281(1):103–108.
   PubMed Web of Science ®Google Scholar
• de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003 Aug;23(4):420–421.
   PubMed Web of Science ®Google Scholar
• de Vos A, van der Weide J, Loovers HM. Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J. 2011 Oct;11(5):359–367.
   PubMed Web of Science ®Google Scholar
• Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol. 2008 Jan;65(1):134–138.
   PubMed Web of Science ®Google Scholar
• Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol. 2011 Sep;7(3):220–223.
   PubMedGoogle Scholar
• Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008 Apr;65(4):558–564.
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó EM, Trejo HD, Dorado P, et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry. 2013 Jan;18(1):8–9.
   PubMed Web of Science ®Google Scholar
• Mandrioli R, Mercolini L, Saracino MA, et al. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2012;19(12):1846–1863.
   PubMed Web of Science ®Google Scholar
• Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother. 2008 Apr;9(5):787–794.
   PubMed Web of Science ®Google Scholar
• Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 2006 May;61(5):558–569.
   PubMed Web of Science ®Google Scholar
• Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Jun;31(6):1274–1285.
   PubMed Web of Science ®Google Scholar
• Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004 Oct;60(8):553–557.
   PubMed Web of Science ®Google Scholar
• Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003 Dec;25(6):738–742.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008 Aug;30(4):474–482.
   PubMed Web of Science ®Google Scholar
• Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002 Aug;22(8):1001–1006.
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992 Mar;51(3):278–287.
   PubMed Web of Science ®Google Scholar
• Sato A, Okura Y, Minagawa S, et al. Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5. Mayo Clin Proc. 2004 Nov;79(11):1444–1448.
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996 Aug;60(2):183–190.
   PubMed Web of Science ®Google Scholar
• Spigset O, Granberg K, Hägg S, et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol. 1997;52(2):129–133.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Sohn KM, Ryu JY, et al. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit. 2006 Jun;28(3):382–387.
   PubMed Web of Science ®Google Scholar
• Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: a Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 march 01;78(3):270–280.
   PubMed Web of Science ®Google Scholar
• Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther. 1998 Oct;64(4):384–390.
   PubMed Web of Science ®Google Scholar
• Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol. 2008 May;64(5):483–487.
   PubMed Web of Science ®Google Scholar
• Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry. 2006 Jun;21(6):542–549.
   PubMed Web of Science ®Google Scholar
• Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012 Jan;68(1):29–37.
   PubMed Web of Science ®Google Scholar
• Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):596–605.
   PubMed Web of Science ®Google Scholar
• Jukic MM, Smith RL, Haslemo T, et al. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019 May;6(5):418–426.
   PubMed Web of Science ®Google Scholar
• Koller D, Belmonte C, Lubomirov R, et al. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. J Psychopharmacol. 2018 11;32(11): 1212–1222.
   PubMed Web of Science ®Google Scholar
• Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012 Oct;66(6):518–524.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Mihara K, Nakamura A, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2011 Feb;33(1):21–24.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Mihara K, Nakamura A, et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2014 Oct;36(5):651–655.
   PubMed Web of Science ®Google Scholar
• van der Weide K, van der Weide J. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. J Clin Psychopharmacol. 2015 Jun;35(3):228–236.
   PubMed Web of Science ®Google Scholar
• Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev Neurother. 2005 May;5(3):297–307.
   PubMedGoogle Scholar
• dailymed.nlm.nih.gov. ARIPIPRAZOLE- aripiprazole tablet [package insert]. Princeton, NJ, USA: Dr.Reddy’s Pharmaceutical Inc;2020. Accessed 03 October, 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0aa7e178-456a-4942-93aa-9ec18a58939f
   Google Scholar
• Koller D, Almenara S, Mejía G, et al. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Hum Psychopharmacol. 2021 01;36(1):1–12.
   PubMed Web of Science ®Google Scholar
• Cabaleiro T, Ochoa D, López-Rodríguez R, et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014 Sep;29(5):459–469.
   PubMed Web of Science ®Google Scholar
• Gassó P, Papagianni K, Mas S, et al. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. Pharmacogenomics. 2013 Oct;14(13):1551–1563.
   PubMed Web of Science ®Google Scholar
• Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol. 2007 Feb;27(1):52–57.
   PubMed Web of Science ®Google Scholar
• Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007 May;40(3):93–102.
   PubMed Web of Science ®Google Scholar
• Novalbos J, López-Rodríguez R, Román M, et al. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010 Oct;30(5):504–511.
   PubMed Web of Science ®Google Scholar
• Jovanović N, Božina N, Lovrić M, et al. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol. 2010 Nov;66(11):1109–1117.
   PubMed Web of Science ®Google Scholar
• Oshikoya KA, Neely KM, Carroll RJ, et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019 04;85(5): 602–606.
   PubMed Web of Science ®Google Scholar
• Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, et al. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627–630.
   PubMed Web of Science ®Google Scholar
• Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175–184.
   PubMed Web of Science ®Google Scholar
• Molden E, Waade RB, Hoff M, et al. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):470–475.
   PubMed Web of Science ®Google Scholar
• Schroth W, Winter S, Mürdter T, et al. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Front Pharmacol. 2017;8:582.
   PubMed Web of Science ®Google Scholar
• Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol. 2014 Apr;77(4):695–703.
   PubMed Web of Science ®Google Scholar
• Jung JA, Lim HS. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. Pharmacogenomics. 2014 Jan;15(1):49–60.
   PubMed Web of Science ®Google Scholar
• Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol. 2007 Sep 01 25(25):3837–3845.
   PubMed Web of Science ®Google Scholar
• Saladores P, Mürdter T, Eccles D, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015 Feb;15(1):84–94.
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Vokinger K, Jetter A, et al. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol. 2014 Jun;73(6):1181–1188.
   PubMed Web of Science ®Google Scholar
• Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012 Mar 21;104(6):452–460.
   PubMed Web of Science ®Google Scholar
• Teh LK, Mohamed NI, Salleh MZ, et al. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1. AAPS J. 2012 Mar;14(1):52–59.
   PubMed Web of Science ®Google Scholar
• Damodaran SE, Pradhan SC, Umamaheswaran G, et al. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy. Cancer Chemother Pharmacol. 2012 Jul;70(1):75–81.
   PubMed Web of Science ®Google Scholar
• Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, et al. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2013 Jul;140(2):363–373.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Johnson A, Quinlan P, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011 Jan;125(1):279–287.
   PubMed Web of Science ®Google Scholar
• Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242–251
   PubMed Web of Science ®Google Scholar
• Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008 Feb;18(2):79–86.
   PubMed Web of Science ®Google Scholar
• Byeon JY, Kim YH, Na HS, et al. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites. Arch Pharm Res. 2015 Nov;38(11):2083–2091.
   PubMed Web of Science ®Google Scholar
• Fijal BA, Guo Y, Li SG, et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015 Oct;55(10):1167–1174.
   PubMed Web of Science ®Google Scholar
• Ramoz N, Boni C, Downing AM, et al. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology. 2009 Aug;34(9):2135–2142.
   PubMed Web of Science ®Google Scholar
• Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225–1230.
   PubMed Web of Science ®Google Scholar
• Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol. 1995 Jun 16;49(12):1777–1784.
   PubMed Web of Science ®Google Scholar
• Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos. 1994 Mar-Apr;22(2):269–274.
   PubMed Web of Science ®Google Scholar
• Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002 Jun 15;20(12):2805–2811.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Lee EH, Rauers NI, et al. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg. 2011 Jul;113(1):48–54.
   PubMed Web of Science ®Google Scholar
• Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol. 2003 Jun;59(2):111–116.
   PubMed Web of Science ®Google Scholar
• Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005 Mar;102(3):543–549.
   PubMed Web of Science ®Google Scholar
• Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 08;102(2):213–218. .
   PubMed Web of Science ®Google Scholar
• Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814–822.
   PubMed Web of Science ®Google Scholar
• Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype–a major determinant of metoprolol metabolism and response. N Engl J Med. 1982 Dec 16;307(25):1558–1560.
   PubMed Web of Science ®Google Scholar
• Blake CM, Kharasch ED, Schwab M, et al. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther. 2013 Sep;94(3):394–399.
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01 94(11):2817–2825
   PubMed Web of Science ®Google Scholar
• Jin SK, Chung HJ, Chung MW, et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther. 2008 Oct;33(5):567–573.
   PubMed Web of Science ®Google Scholar
• Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther. 2009 Mar;85(3):269–272.
   PubMed Web of Science ®Google Scholar
• Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004 Dec;76(6):536–544.
   PubMed Web of Science ®Google Scholar
• Hamadeh IS, Langaee TY, Dwivedi R, et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther. 2014 Aug;96(2):175–181.
   PubMed Web of Science ®Google Scholar
• Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther. 2005 Mar;77(3):127–137.
   PubMed Web of Science ®Google Scholar
• Frost DA, Soric MM, Kaiser R, et al. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors. Pharmacotherapy. 2019 06;39(6):724–729.
   PubMed Web of Science ®Google Scholar
• Kiss Á, Menus Á, Tóth K, et al. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. Eur Arch Psychiatry Clin Neurosci. 2020 Feb;270(1):71–82.
   PubMed Web of Science ®Google Scholar
• Klomp SD, Manson ML, Guchelaar HJ, et al. Phenoconversion of Cytochrome P450 Metabolism: a Systematic Review. J Clin Med. 2020 Sep 07 9(9):2890
   PubMed Web of Science ®Google Scholar
• Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J. 2020 06;20(3):355–366.
   PubMed Web of Science ®Google Scholar
• Lesche D, Mostafa S, Everall I, et al. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics J. 2020 04;20(2): 192–201.
   PubMed Web of Science ®Google Scholar
• Storelli F, Matthey A, Lenglet S, et al. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions. Clin Pharmacol Ther. 2018 07;104(1): 148–157.
   PubMed Web of Science ®Google Scholar
• Monte AA, Heard KJ, Vasiliou V. Prediction of drug response and safety in clinical practice. J Med Toxicol. 2012 Mar;8(1):43–51.
   PubMedGoogle Scholar
• Ahern TP, Hertz DL, Damkier P, et al. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol. 2017 jan 15;185(2):75–85.
   PubMed Web of Science ®Google Scholar
• Monte AA, Heard KJ, Campbell J, et al. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879–885.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Hosono N, et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics. 2010 Sep;20(9):565–568.
   PubMed Web of Science ®Google Scholar
• Gloor Y, Lloret-Linares C, Bosilkovska M, et al. Drug metabolic enzyme genotype-phenotype discrepancy: high phenoconversion rate in patients treated with antidepressants. Biomed Pharmacother. 2022 Aug;152:113202.
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013 Jun;74(6):614–621.
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122–1138.
   PubMedGoogle Scholar
• Kiss Á, Vaskó D, Déri MT, et al. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction. Pharmacol Rep. 2018 Jun;70(3):525–532.
   PubMed Web of Science ®Google Scholar
• de Souza Ja, Olopade OI, de Souza JA. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol. 2011 Apr;38(2):263–273.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Pritchard KI. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst. 2012 Mar 21;104(6):427–428
   PubMedGoogle Scholar
• Thomas CD, Parvataneni HK, Gray CF, et al. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genet Med. 2021 04;23(4):621–628. .
   PubMed Web of Science ®Google Scholar
• Smith DM, Weitzel KW, Elsey AR, et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med. 2019 08;21(8):1842–1850. .
   PubMed Web of Science ®Google Scholar
• Desmeules J, Gascon MP, Dayer P, et al. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol. 1991;41(1):23–26.
   PubMed Web of Science ®Google Scholar
• Matos A, Bankes DL, Bain KT, et al. Opioids, Polypharmacy, and Drug Interactions: a Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic. Pharmacy (Basel). 2020 Aug 25;8:(3):154.
   PubMedGoogle Scholar
• Fulton CR, Zang Y, Desta Z, et al. Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics. 2019 04;20(6): 397–408.
   PubMed Web of Science ®Google Scholar
• Michaud V, Bikmetov R, Smith MK, et al. Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs. J Pers Med. 2021 Nov 10 11(11):1174.
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Cicali E, Wiisanen K, et al. Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators. Clin Transl Sci. 2022 Jul 28;15:2479–2492.
   PubMed Web of Science ®Google Scholar
• Jallaq SA, Verba M, Strawn JR, et al. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. J Child Adolesc Psychopharmacol. 2021 02;31(1): 56–62.
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006 Jul;80(1):61–74.
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson, MD, Rae, JM et al , et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 03;95(23):1758–1764.
   PubMedGoogle Scholar
• Haque R, Shi J, Schottinger JE, et al. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar;108(3).
   Google Scholar
• Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010 Feb 08;340:c693.
   PubMedGoogle Scholar
• Jung EH, Lee YJ, Kim DH, et al. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res. 2020 Dec;43(12):1356–1363.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bae JW, Jeong CH, et al. Drug-Drug Interaction of Paroxetine and Atomoxetine in Different CYP2D6 Genotypes. Clin Ther. 2016 Oct 06;38(10S):e23.
   PubMedGoogle Scholar
• Paulzen M, Clement HW, Gründer G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol. 2008 Mar;11(2):289–291.
   PubMed Web of Science ®Google Scholar
• Todor I, Popa A, Neag M, et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513–520.
   PubMedGoogle Scholar
• Todor I, Popa A, Neag M, et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016 Apr-Jun;19(2):198–207.
   PubMed Web of Science ®Google Scholar
• Naguy A, Al-Mutairi H, Al-Tajali A. Atomoxetine-related Takotsubo Cardiomyopathy. J Psychiatr Pract. 2016 05;22(3):232–233.
   PubMed Web of Science ®Google Scholar
• cpicpgx.org. https://cpicpgx.org/prioritization-of-cpic-guidelines/ Last accessed on October 11, 2022.
   Google Scholar
• Pratt VM, Cavallari LH, Del Tredici AL, et al. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: a Joint Consensus Recommendation of the Association for Molecular Pathology, College of American PathologistsDutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn. 2021 09;23(9):1047–1064.
   PubMed Web of Science ®Google Scholar
• Cicali EJ, Wiisanen K. The importance of phenoconversion when using the CYP2D6 genotype in clinical practice. Pharmacogenomics. 2022 09;23(14):749–752. .
   PubMed Web of Science ®Google Scholar
• Arwood MJ, Chumnumwat S, Cavallari LH, et al. Implementing Pharmacogenomics at Your Institution: establishment and Overcoming Implementation Challenges. Clin Transl Sci. 2016 Oct;9(5):233–245.
   PubMed Web of Science ®Google Scholar
• Arwood MJ, Dietrich EA, Duong BQ, et al. Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. J Clin Med. 2020 Jul 17 9(7):2274.
   PubMed Web of Science ®Google Scholar
• Cicali EJ, Weitzel KW, Elsey AR, et al. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. Genet Med. 2019 10;21(10): 2264–2274.
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Duong BQ, Arwood MJ, et al. A stepwise approach to implementing pharmacogenetic testing in the primary care setting. Pharmacogenomics. 2019 10;20(15):1103–1112. .
   PubMed Web of Science ®Google Scholar